N. meningitidis group C (MenC) capsular polysaccharide (␣2,9-Nacetyl neuraminic acid) results in the production of Abs where V H and V L are encoded by a restricted family of unmutated or nearly unmutated germline Ig genes, regardless of whether the polysaccharide has been conjugated to a carrier protein (15, 16 ). In contrast, zwitterionic polysaccharides can be processed and presented on MHC class II molecules and can activate T cells, and they are thus T-dependent Ags (12) (13) (14) .
This study examines whether the presence of de-N-acetylated residues in NPr MBPS is important for eliciting Abs that are protective against MenB bacteria without also being cross-reactive with PSA. Four anti-NPr MBPS mAbs (SEAM 2, 3, 12, and 18) described by Granoff et al. (6) were used to characterize de-Nacetylated residue-containing PSA derivatives (de-N-acetyl PSA). All four mAbs are protective against MenB strains. SEAM 2 and 3 are reactive with PSA derivatives that contain de-N-acetyated residues (Ref. 9 and see below) but not with normal human PSA Ags such as that expressed on neural cell adhesion molecule (NCAM) (3) . In contrast, SEAM 12 and 18 are reactive with NCAM PSA (6) . SEAM 12 is also weakly reactive with poly-␣2,8-neuraminic acid (see Table II ). In the following, we describe the results of immunogenicity studies of four de-N-acetyl PSA derivative tetanus toxoid (TT) conjugate vaccines in CD1 mice and the functional activity of Abs elicited by the vaccines against MenB and MenC strains.
Materials and Methods

Preparation of polysaccharide Ags de-N-acetyl poly-␣2,8-neuraminic acid (DeNAc).
Colominic acid (100 mg; Sigma-Aldrich) and sodium borohydride (10 mg) were suspended in water (8.8 ml). The solution was heated to 90-100°C for 2 h after adding NaOH (1.8 ml of 50% solution; Fisher Scientific) to a final NaOH concentration of 2 M. After cooling the solution to ambient temperature, 2 M HCl was added to adjust the pH to 8. Precipitates were removed by centrifugation, the supernatant solution was dialyzed against 2 ϫ 4 liters of water (1 kDa Spectrum Spectra/Por*7 dialysis membrane; Fisher Scientific) and lyophilized. N-Trichloroacetyl PSA (TcAc). DeNAc (50 mg) was suspended in water (5 ml) and the pH adjusted to 8-9 with 2 M NaOH. Trichloroacetyl chloride (Sigma-Aldrich) was added to the stirred solution in five 0.1-ml aliquots during a period of 1 h. The pH was maintained between 8 and 9 by adding 2 M NaOH. The reaction mixture was dialyzed in water and lyophilized as described above. N-propionyl PSA (NPr) and Sialidase A-treated N-propionyl PSA (NPrSia). NPr was prepared as described for TcAc except that propionic anhydride (Sigma-Aldrich) was used in place of the acid chloride. Exoneuraminidases are unable to degrade or degrade much slower PSA that contains neuraminic acid (Neu) at the nonreducing end (T. S. Bhandari and G. R. Moe, unpublished) . Therefore, a portion (20 mg) of the NPr derivative was further treated with the exoneuraminidase Sialidase A (ProZyme; 0.1 U/mg of polysaccharide) to increase the fraction of molecules that terminate at the nonreducing end in Neu. The polysaccharide was incubated with Sialidase A in 50 mM sodium phosphate buffer (pH 7) at 37°C for 2 days. The reaction mixture was dialyzed in water and lyophilized as described above.
Conjugation of polysaccharide Ags to TT carrier protein
The polysaccharide derivatives with the exception of NPr were oxidized by combining sodium periodate (5 mol) and 20 mg of polysaccharide (ϳ1 equivalent of periodate for every 10 residues) in 2 ml of 0.1 M sodium acetate buffer (pH 6.5) and incubating for 1 h. NPr (20 mg) was oxidized with 5 mg of sodium periodate in 1 ml of 0.1 M sodium acetate buffer (pH 6.5) for 30 min. Ethylene glycol (100 l of a 10% (v/v) solution in water) was added to destroy any remaining periodate, and the solution was dialyzed and lyophilized as described above.
To conjugate the polysaccharide derivative to TT, 10 mg of oxidized de-N-acetyl PSA derivative was combined with 5 mg of TT (BioVeris) in PBS buffer and allowed to stir at ambient temperature overnight. The following day, 5 mg of sodium cyanoborohydride (Sigma-Aldrich) was added, and stirring of the mixture was continued overnight. The next day, sodium sulfate was added to 0.5 M and the mixture again stirred overnight.
The vaccine preparation was dialyzed against 4 liters of PBS buffer, sterile filtered (0.22-m filter), divided into aliquots, and stored at Ϫ80°C until used.
Measurement of sialic acid concentrations
The concentration of N-acetyl neuraminic acid (NeuNAc) and Neu in the de-N-acetyl PSA derivative preparations was determined by a modification of the Svennerholm resorcinol reaction modified as follows. The resorcinol working reagent (300 l) was combined with the sialic acid or de-N-acetyl sialic acid sample solution (up to 50 g of sialic acid) or standard stock solution of NeuNAc or de-N-acetyl colominic acid in water (300 l) in a polypropylene deep well (2 ml) microtiter plate (Fisher Scientific). The plate was sealed with a plate cover and heated in a boiling water bath for 30 min. After cooling to ambient temperature, isoamyl alcohol (600 l) was added and mixed using a pipette. The phases were allowed to separate and the upper isoamyl alcohol layer was removed to a clean microtiter plate. The isoamyl alcohol extract and the lower aqueous solution (250 l each) were transferred separately to a polystyrene microtiter plate and the absorbance at 495 and 580 nm was measured using a SpectraMax microtiter plate reader (Molecular Devices). The amount of NeuNAc was determined from the absorbance of the isoamyl alcohol fraction at 580 nm, and the amount of Neu was determined from the absorbance of the aqueous fraction at 495 nm in comparison to a standard curve for each. The amount of Neu was corrected for the amount of de-N-acetylation that occurs during the acid hydrolysis step of the assay by measuring the amount of de-Nacetylation that occurs in the NeuNAc standard.
Western blot
The de-N-acetyl PSA derivative-TT conjugates were tested for their ability to bind the anti-NPr mAbs SEAM 2, 3, and 18 (6) by Western blot. Each conjugate (36 g of total sialic acid) was separated on a 4 -15% SDSpolyacrylamide gradient gel (Bio-Rad Laboratories) and transferred to nitrocellulose (Bio-Rad Laboratories) using a Trans-Blot SD SemiDry transfer cell (Bio-Rad Laboratories). The membrane was blocked for at least 1 h in 5% (w/v) nonfat milk in PBS buffer. The mAbs SEAM 2 (20 g/ml), SEAM 3 (0.24 g/ml), and SEAM 18 (42 g/ml) were incubated with the blocked membranes at ambient temperature overnight. After extensive washing with PBS buffer, bound Abs were detected using a rabbit antimouse IgG polyclonal Ab conjugated to HRP (Zymed Laboratories) and Western Lightning chemiluminescence reagents (PerkinElmer Life and Analytical Sciences).
Immunogenicity in mice
The immunogenicity of the de-N-acetyl PSA derivative-TT conjugates prepared above was evaluated in CD1 mice. All animal experiments were approved by the Children's Hospital Oakland Research Institute Institutional Animal Care and Use Committee. Groups of 10 female CD1 mice (6 -8 wk old; Charles River Laboratories) were immunized with de-Nacetyl PSA derivative-TT conjugate vaccine in 50% (v/v) of 0.9% saline and 50% (v/v) Freund's complete adjuvant (Pierce Biotechnology) emulsion by i.p. injection. Each dose contained 1-2 g of de-N-acetyl sialic acid (i.e., Neu). Blood samples were obtained from the submandibular vein of the mice 10 days after each injection, and the anti-de-N-acetyl PSA derivative titers were determined by ELISA using de-N-acetyl PSA derivative-BSA conjugates as solid-phase Ags as described below.
Booster doses of IFA (Pierce) were given at 28 days after primary immunization, and titers of antisera obtained 10 days postimmunization were evaluated by ELISA. At 56 days after primary immunization, the groups were split in half. Five mice from each group were given unconjugated de-N-acetyl PSA derivative and the other five were given conjugated de-N-acetyl PSA derivative, both without adjuvant. Since the Ab responses of the mice that had received the unconjugated de-N-acetyl PSA derivative were minimal (titer Յ1/200), they were given a third dose of conjugate without adjuvant 112 days after primary immunization. The antisera from the latter group were found to be equivalent with respect to anti-DeNAc titer and to functional activity of the group that was given conjugate only and were used interchangeably as three-dose antisera in the assays described below.
ELISA
The anti-de-N-acetyl PSA derivative titer elicited by the vaccines was measured by ELISA using de-N-acetyl PSA derivatives conjugated to BSA prepared as described above for the de-N-acetyl PSA derivative-TT conjugates. Initially, antiserum from each mouse was tested individually, but since the titers were similar (Ͻ10-fold difference) for individuals in the group, the antisera from mice in each group were pooled and all additional experiments were done with pooled antisera. ELISA plates were prepared by coating the de-N-acetyl PSA derivative-BSA conjugate (5 g of total de-N-acetyl PSA derivative) in wells of a 96-well microtiter plate (Immunon II HB; Dynatech) overnight at 4°C before use. Blocking the plates, adding dilutions of antisera in blocking buffer (PBS containing 1% BSA), and developing the ELISA was performed as described previously (6) . The specificity of binding was tested by inhibition ELISA performed as described above, with the addition of 50 g/ml soluble de-N-acetyl PSA derivative as the inhibitor. Titer was defined as the dilution giving half maximal response after 1 h of color development.
Bacterial binding assays
Ab binding to MenB was measured by flow cytometry as described by Granoff et al. (6) . FITC-conjugated anti-mouse IgM and IgG1, IgG2a, IgG2b, and IgG3 (Bethyl Laboratories) were used to detect bound Abs.
Activation of human complement protein deposition
The ability of Abs elicited by immunization with de-N-acetyl PSA derivative conjugate vaccines to activate deposition of human complement proteins (anti-C3c) on meningococcal bacteria was determined as described by Welsch et al. (17) .
Serum bactericidal assay (SBA)
The ability of the antisera to mediate bacteriolysis in the presence of exogenous human complement was measured by the SBA using complement from a human donor that lacks Abs to the test strain as described by Moe et al. (9) , except that Dulbecco's buffered saline was used in place of Gey's buffer.
Infant rat passive protection assay
Infant (4-to 6-day-old) Wistar rats were taken from the mothers and randomly divided into groups of five pups each. Each rat was given 100 l of antiserum diluted 1/10 in sterile PBS containing 1% BSA i.p. and then returned to their mothers while the challenge bacteria were prepared. MenB strain M986 was grown to OD 620 nm of 0.6 in Mueller-Hinton broth with 0.25% glucose, washed, resuspended in PBS with 1% BSA, and diluted in the same buffer. Each rat pup was given a challenge dose of 10,400 CFU in 100 l of buffer. The pups were randomly returned to a mother. The next day, the pups were anesthetized with isoflurane and blood was obtained by cardiac puncture using a heparanized needle. The animals were euthanized by CO 2 anoxia, and 100, 10, and 1 l of the blood was plated on chocolate agar (Remel). The plates were incubated at 37°C, 5% CO 2 overnight and then the colonies were counted using a ProtoCOL plate reader (Synoptics).
Results
Vaccine characteristics
Four de-N-acetyl PSA derivatives as shown in Fig. 1 were prepared. The amounts of N-acyl neuraminic acid, Neu, and protein are compared in Table I . The ratio of polysaccharide to protein is higher than is typically obtained in the conjugation reaction (4, 6, 8) , which may suggest that some of the polysaccharide was linked to other polysaccharide chains producing branched structures or that unconjugated polysaccharide aggregates with polysaccharide linked to the carrier protein.
The NPr conjugate was synthesized as a positive control (6), although it differs from the original NPr-TT conjugate vaccine in that the NPr Ag was not purified to isolate derivatives with a limited degree of polymerization range. Thus, the NPr Ag used in this study contained both shorter and longer polymers than the vaccine used to produce the prototypical SEAM 2 and 3 mAbs. In this instance, we chose not to purify the derivatives because we have observed that oliogmers as small as a trimer containing as little as 20% de-N-acetyl residues form high-molecular-mass aggregates in solution (B. T. Hagen and G. R. Moe, unpublished observations). As a result, purification of intermediate-sized fragments by size exclusion chromatography has the effect of removing derivatives that are reactive with SEAM 2 and 3.
A portion of the NPr derivative was treated with Sialidase A, an exoneuraminidase that progressively removes NeuNAc residues from the nonreducing end (18) until the enzyme encounters a de-N-acetylated residue. The enzyme is either unable to remove de-N-acetylated residues or the rate of hydrolysis is considerably slower (T. S. Bhandari and G. R. Moe, unpublished observations). Thus, treating de-N-acetyl PSA derivatives with Sialidase A results in an increase in the number of chains terminating at the nonreducing end in de-N-acetylated residues. The NPrSia-TT conjugate was more reactive with SEAM 3 and less reactive with SEAM 18 (Table II and Fig. 2 ) than was the parent NPr derivative that had not been treated with Sialidase A.
For reasons that are unknown, the TcAc conjugate is ϳ1000-fold more reactive with SEAM 2 (Fig. 2) than is the NPr derivative as determined by ELISA (Table II) . The N-trichloroacetyl group is removable under milder conditions than is the N-acetyl group. Originally, the TcAc derivative was synthesized with the idea of preparing de-N-acetyl PSA derivatives with variable amounts of de-N-acetyl residues by selective removal of the protecting group under conditions that could be more easily controlled. Although the van der Waal volume of the trichloroacetyl group is similar to the N-propionyl group, it was only slightly reactive with SEAM 3, 12, and 18 by ELISA (Table II) or with SEAM 3 on Western blots (Fig. 2) . SEAM 12 and 18 are reactive with host PSA Ags (6, 19) and were used to show the lack of autoreactive PSA epitopes in the Ag.
Lastly, the DeNAc conjugate was weakly reactive with SEAM 12 (Table II) but was not reactive with SEAM 2, 3, or 18 (Table  II and Fig. 2 ), even though SEAM 3 has been shown to recognize PSA Ags containing a small fraction (ϳ20%) of de-N-acetylated residues (9) . As with the NPrSia derivative, the DeNAc derivative is enriched for polymer chains that terminate at the nonreducing end in de-N-acetylated residues since it was almost completely de-N-acetylated. Thus, the four vaccine Ags contained a range of PSA/de-N-acetyl PSA epitopes and de-N-acetylated residue content with which to evaluate the question of whether de-N-acetyl PSA-based vaccines can be designed to elicit protective Ab responses to MenB without also eliciting Abs that are cross-reactive with host PSA Ags.
Vaccine immunogenicity
The Ab titers for the homologous PSA derivative after each immunization were similar for individual mice, and, therefore, the antisera of each group were pooled for all subsequent characterization. Ab responses to the NPr-and TcAc-TT conjugate vaccines for the homologous Ags were very poor (Fig. 3A) . In contrast, the NPrSia and DeNAc conjugate vaccines elicited high Ab titers that reached a maximum after two doses (Fig. 3A) . Since the NPrSia and DeNAc PSA derivatives where enriched for nonreducing end de-N-acetyl residues, we compared the reactivity of the pooled sera with the DeNAc derivative and found that all four vaccines elicited high (Ն1/10,000) anti-DeNAc Ab titers after the third dose that were only slightly increased over those of the second immunization (Fig. 3B) . Even though the fractional amount of de-N-acetyl residues in each vaccine varied over a wide range (from 7% to 98%), all the vaccines elicited anti-DeNAc titers of roughly the same magnitude. This suggests that the nonreducing end, zwitterionic de-N-acetyl residue component in all of the de-N-acetyl PSA Ags was immunogenic and was the immunodominant determinant of the vaccines.
The antisera were also tested by ELISA for their ability to bind to PSA. All showed minimal color development (OD 405 nm of Ͻ0.1) after 2 h incubation with substrate that was not different from that of mice immunized with tetanus toxoid alone or from unimmunized mice at dilutions of 1/50 (the lowest dilution tested; data not shown). The result shows that the vaccines did not elicit PSA-reactive Abs even though two of the vaccines (NPr and NPrSia) contained relatively large fractions of N-acyl groups. Reactivity with PSA has been associated with cross-reactivity with human PSA Ags (5, 6, 20) . The lack of PSA cross-reacting Abs is consistent with the fact that PSA derivatives containing de-Nacetyl residues exhibit physical and chemical properties that are distinct from PSA. Obviously, this is especially true for the DeNAc Ag, which is almost completely de-N-acetylated. The specificity of the antisera for the homologous de-N-acetyl PSA derivative and DeNAc Ags was evaluated by inhibition ELISA in the presence of 50 g/ml soluble DeNAc polysaccharide. However, binding actually increased slightly (10 -20%) in the presence of soluble inhibitor compared with the antisera alone. The increased binding observed may result from aggregation of soluble Ag and surface-associated Ag and/or cross-linking by the Ab between surface-bound and soluble Ags. As noted above, even small PSA oligosaccharides that contain a fraction of de-N-acetylated residues readily aggregate in solution to form high-molecular-mass complexes.
Binding to live MenB bacteria
As shown in Fig. 4A , the TT carrier protein and the NPr and TcAc conjugate vaccines elicited Abs that were weakly reactive with MenB strain NMB. The NMB-reactive Abs were primarily class IgM. In contrast, the two vaccines that were enriched for nonreducing end de-N-acetylated residues elicited IgM and IgG Abs of all subclasses that were reactive with NMB. PSA or MBPS, even when conjugated to a carrier protein, elicits mainly IgM Abs in mice with the exception of rare IgG mAbs that have been produced in New Zealand Black mice that have a propensity to produce autoreactive Abs (19, 22) .
The ability of zwitterionic PSA derivatives of normally nonimmunogenic PSA to elicit IgG Abs suggests that they may provide T cell help through the mechanism of zwitterionic polysaccharide processing and presentation on MHC class II molecules described by Cobb and Kasper (12) . Similarly, Gallorini et al. have recently shown that introducing a zwitterionic motif into naturally anionic bacterial polysaccharides confers the ability to activate both T cells and APCs such as monocytes and dendritic cells (23) . Thus, some, but not all (23) , zwitterionic polysaccharides are T-dependent Ags that, as shown here, can elicit IgM and IgG Ab responses.
Activation of human complement
All the antisera strongly activated complement protein (C3) deposition on MenB strain NMB (Fig. 4B) , and there was little difference in the amount of complement deposited between the antisera elicited by different Ags. The uniformity in the ability of each vaccine antiserum to activate complement is in accordance with the similarity seen in the anti-DeNAc ELISA titers (Fig. 3B) and the fact that all four vaccines elicited IgM Abs that could bind to MenB (Fig. 4A) .
Passive protection in infant rats
Several studies have shown a correlation between the ability to activate complement protein deposition on MenB bacteria and passive protection in the infant rat model of meningococcal bacteremia (17) . As shown in Fig. 5 , the antisera from the mice immunized with the TT carrier protein alone did not protect the rat pups from challenge by MenB strain M986. All pups treated with the TT antisera were bacteremic and had high blood culture titers of bacteria (Ͼ50,000 CFU/ml). The positive control mAb SEAM 2 was completely protective (sterile blood cultures) at a dose of 6 g of mAb per pup. Similarly, pups treated with the 10 l of anti-de-Nacetyl PSA derivative-TT sera were either completely protected (sterile blood cultures) or had reduced CFU burden compared with the pups that received the control TT antisera. Protection by vaccine antisera was significantly different than the control TT antisera ( p Ͻ 0.05) with protection by the TcAc antisera being just short of signficance ( p ϭ 0.1).
Serum bactericidal activity
The antisera were tested for their ability to mediate SBA against MenB strain NMB. Despite showing strong activation of complement protein deposition against this strain (Fig. 4B ) and passive protection against MenB strain M986 (Fig. 5) , none of the vaccine antisera was able to mediate bacteriolysis of NMB in the presence of human complement (data not shown). The result is perhaps not unexpected based on functional characteristics exhibited by SEAM 2 and 3. SEAM 3 is not bactericidal with human complement (6) and SEAM 2 requires very high Ab concentrations (Ͼ200 g/ml) (24). However, both mAbs can activate human complement protein deposition and can passively protect in the infant rat model of MenB bacteremia at mAb concentrations on the order of 1 g/ml or less (e.g., see Figs. 4B and 5) .
Recently, we discovered that the Ags recognized by SEAM 2, 3, and 18 are expressed in all meningococcal serogroups that express sialic acid-containing capsular polysaccharides (i.e., MenB, MenC, N. meningitidis group Y, and W135 (24)). Furthermore, all three mAbs can mediate bactericidal activity against MenC strains with human complement (24) . Therefore, we tested SBA against MenC strain 4243 with human complement. As shown in Table III , the NPr, DeNAc, and TcAc antisera pools showed complement-mediated bactericidal activity against the MenC strain, but the NPrSia and TT antisera had no activity in three independent assays. Thus, the differences in SBA activity of the vaccine antisera between MenB and MenC strains is a characteristic shared by SEAM 2 and 3, the prototypical mAbs used to develop the de-N-acetyl PSA derivatives used in this study.
Discussion
A subset of Abs elicited by NPr MBPS-TT conjugate vaccines have the surprising characteristics of being either unreactive or poorly reactive with purified MBPS yet are able to mediate protective responses against MenB bacteria including activation of complement protein deposition (e.g., see SEAM 2; Fig. 4B ), complement-dependent bactericidal activity (6, 8, 9) , and passive protection in an infant rat model of meningococcal bacteremia (6) . In a previous study, we showed that the anti-NPr MBPS mAb SEAM 3 recognizes de-N-acetyl PSA-containing derivatives (9) . Since SEAM 3 binds to MenB bacteria, activates complement protein deposition, and can passively protect against a MenB bacterial challenge in an infant rat model of meningococcal bacteremia, this suggests that MenB expresses de-N-acetyl PSA Ags. While it is possible that mAbs such as SEAM 2 and 3 are cross-reactive with unknown non-PSA-derived Ags, we consider that possibility unlikely. The specificity of both SEAM 2 and 3 have been studied extensively with a broad range of molecules, including polysaccharides, polysaccharide derivatives (9) , and phage display (11) and combinatorial small molecule libraries (25) . Also, de-N-acetyl PSA derivatives must be immunogenic since Abs such as SEAM 3 were elicited in response to immunization with NPr MBPS-protein conjugate vaccines that contained de-N-acetylated sialic acid residues. The purpose of the present study was to determine whether de-N-acetyl PSA derivative-TT conjugate vaccines in which the PSA derivatives were specifically reactive with mAbs SEAM 2 and 3, which are protective against MenB bacteria but are not reactive with purified MBPS, can elicit similarly protective but not autoreactive Abs.
The results of this study show that de-N-acetyl PSA derivatives are immunogenic. Relatively small doses (ϳ1 g) of de-N-acetylated residues in a de-N-acetyl PSA derivative can elicit Abs that bind to MenB and MenC bacteria, activate complement, and passively protect in an infant rat model of meningococcal bacteremia. Derivatives enriched for nonreducing end de-N-acetyl residues may be particularly efficient in eliciting IgG Abs of all subclasses. The polyclonal antisera were not reactive with purified PSA. It is therefore likely that one explanation for the ability of NPr MBPSbased vaccines to elicit protective but not autoreactive Abs is that the NPr MBPS vaccine contains some fraction of de-N-acetylated residues.
PSA that contains de-N-acetyl residues is physically and chemically different than unmodified PSA. The differences are no doubt critical in accounting for the vastly different Ab responses to the two Ags. PSA, even when conjugated to a carrier protein, is very poorly immunogenic, eliciting predominantly IgM responses where the Abs are encoded by unmutated germline V H and V L genes, and it fails to induce immunologic memory. In contrast, zwitterionic de-N-acetyl PSA Ags elicited high titers of IgM and IgG Abs of all subclasses. Polysaccharides that contain zwitterionic residues can be processed differently from uncharged or negatively charged polysaccharides and presented on MHC class II molecules to stimulate helper T cells (12, 14, 23) . Therefore, it is likely that the presence of zwitterionic Neu residues, particularly at the nonreducing end of de-N-acetyl PSA derivatives, is critical for eliciting the observed Ab responses.
Although bactericidal activity is widely accepted as a surrogate of protection against meningococcal disease, it may underestimate protection (26) . In particular, MenB is known to be resistant to SBA and more sensitive to opsonophagocytosis than other serogroups (27) , and it is possible that opsonophagocytosis is a major element of protective immunity to disease caused by MenB. Lack of SBA, therefore, may not necessarily correlate with lack of protection against MenB strains. AntiMenB mAbs have been described that are protective but not bactericidal (17, 28, 29) , and Toropainen et al. have reported that IgM-mediated protection against MenB as measured by the infant rat protection assay is independent of complement-mediated bacteriolysis (30) .
The NPr, TcAc, and DeNAc antiserum pools were able to mediate SBA against MenC strain 4243. The result demonstrates that there is no intrinsic lack of bactericidal functionality of Abs that are reactive with de-N-acetyl sialic acid-containing Ags expressed by meningococcal strains, but that activity can be affected by the a Serum bactericidal titers were defined as the serum dilution resulting in a 50% decrease in CFU/ml after 60 min of incubation of bacteria in the reaction mixture, compared to the control CFU/ml at time 0. Typically, bacteria incubated with the negative control Ab and complement showed a 150 -200% increase in CFU/ml during the 60 min of incubation.
presence of structurally related PSA Ags (e.g., MBPS poly-␣2,8-N-acetyl neuraminic acid). Similar results have been observed for the prototypic mAbs SEAM 2 and 3. Neither mAb is reactive with MCPS or MCPS containing de-N-acetyl sialic acid, but both mAbs exhibit greater binding to MenC strains and are able to mediate bactericidal activity at lower Ab concentrations than MenB strains (24) . Thus, it appears that both MenB and MenC strains express poly-␣2,8-N-acetyl neuraminic acid Ags that contain nonreducing end de-N-acetyl sialic acid (neuraminic acid) that can be the target of protective Abs elicited by de-Nacetyl PSA-containing vaccines.
Collectively, MenB and MenC strains cause 50% to Ͼ90% of meningococcal disease in developed countries (1) . Although the functional activity of the de-N-acetyl PSA derivative antisera was evaluated using only a few strains in this study, a large number of genetically diverse MenB strains isolated from patients from many countries over a period of several decades and grown under a variety of conditions including human blood and plasma have been found to express Ags reactive with SEAM 2 and 3 (B. A. Flitter, J. Y. Ing, and G. R. Moe, unpublished observations). Therefore, optimized vaccines based on de-Nacetyl PSA derivatives have the potential to provide protection against the majority of meningococcal disease occurring in developed countries.
It is unclear at present whether de-N-acetyl PSA or de-N-acetyl sialic acid Ags are expressed in normal adult or fetal tissues. Hakomori and coworkers identified de-N-acetyl monosialoganglioside GM3 in A431 epithelial carcinoma and B16 melanoma cell lines (31) . Subsequently, Varki and coworkers identified de-Nacetyl derivatives of the disialoganglioside GD3 using mAbs (32, 33) . By immunohistochemcial staining, they showed that de-Nacetyl GD3 was expressed at low levels in a few blood vessels, infiltrating mononuclear cells in the skin and colon, and at moderate levels in skin melanocytes (32) . Using radioactive labeling experiments in melanoma cell lines, Manzi et al. (34) showed that N-acetyl groups in gangliosides GD3 and GM3 turned over more rapidly than did the parent molecules, suggesting the existence of a sialic acid de-N-acetylase for the production of de-N-acetyl gangliosides in these cells. Recently, Popa et al. isolated and determined the structure of de-N-acetyl GD3 from primary human melanoma tumor (35) . The de-N-acetylated residue was shown to be at the nonreducing end of the dimer, while the reducing end residue of the disialolyl moiety was N-acetylated. We have observed by immunohistochemistry analysis that several primary human tumors including melanoma, neuroblastoma, leukemia, and tumors of the stomach, ovary, and uterus express Ags recognized by SEAM 3 and polyclonal antide-N-acetyl PSA sera that are distinct from PSA expressed on NCAM and that were not detected in the corresponding normal tissues (C.P. Plested, H. Kaur, and G. R. Moe, unpublished observations). SEAM 3, however, does not react with de-Nacetylated GD3 derivatives (G. R. Moe and G. S. Mittendorf, unpublished observations). Understanding the biology of de-Nacetyl sialic acid Ag expression in normal and diseased tissues will be essential for establishing whether de-N-acetyl PSAbased vaccines can be safe for general use in humans to protect against meningococcal disease. Abs that can be produced using the de-N-acetyl PSA vaccines described herein will be important in reaching that goal as well as for understanding the role of de-N-acetyl sialic acid Ags in human health and disease.
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